S&P 500   4,362.75 (-0.90%)
DOW   34,298.76 (-0.41%)
QQQ   360.86 (-1.01%)
AAPL   175.31 (-0.10%)
MSFT   321.97 (+0.37%)
META   299.96 (+0.10%)
GOOGL   131.80 (-1.45%)
AMZN   130.86 (-3.27%)
TSLA   259.57 (-1.15%)
NVDA   415.18 (-1.71%)
NIO   8.54 (-3.17%)
BABA   84.48 (-1.47%)
AMD   97.36 (-2.97%)
T   15.36 (-1.22%)
F   12.25 (-0.89%)
MU   68.96 (-1.03%)
CGC   0.83 (-5.23%)
GE   113.85 (-0.87%)
DIS   83.38 (+0.99%)
AMC   7.87 (-3.55%)
PFE   33.11 (-1.52%)
PYPL   58.93 (-3.17%)
NFLX   388.06 (+0.46%)
S&P 500   4,362.75 (-0.90%)
DOW   34,298.76 (-0.41%)
QQQ   360.86 (-1.01%)
AAPL   175.31 (-0.10%)
MSFT   321.97 (+0.37%)
META   299.96 (+0.10%)
GOOGL   131.80 (-1.45%)
AMZN   130.86 (-3.27%)
TSLA   259.57 (-1.15%)
NVDA   415.18 (-1.71%)
NIO   8.54 (-3.17%)
BABA   84.48 (-1.47%)
AMD   97.36 (-2.97%)
T   15.36 (-1.22%)
F   12.25 (-0.89%)
MU   68.96 (-1.03%)
CGC   0.83 (-5.23%)
GE   113.85 (-0.87%)
DIS   83.38 (+0.99%)
AMC   7.87 (-3.55%)
PFE   33.11 (-1.52%)
PYPL   58.93 (-3.17%)
NFLX   388.06 (+0.46%)
S&P 500   4,362.75 (-0.90%)
DOW   34,298.76 (-0.41%)
QQQ   360.86 (-1.01%)
AAPL   175.31 (-0.10%)
MSFT   321.97 (+0.37%)
META   299.96 (+0.10%)
GOOGL   131.80 (-1.45%)
AMZN   130.86 (-3.27%)
TSLA   259.57 (-1.15%)
NVDA   415.18 (-1.71%)
NIO   8.54 (-3.17%)
BABA   84.48 (-1.47%)
AMD   97.36 (-2.97%)
T   15.36 (-1.22%)
F   12.25 (-0.89%)
MU   68.96 (-1.03%)
CGC   0.83 (-5.23%)
GE   113.85 (-0.87%)
DIS   83.38 (+0.99%)
AMC   7.87 (-3.55%)
PFE   33.11 (-1.52%)
PYPL   58.93 (-3.17%)
NFLX   388.06 (+0.46%)
S&P 500   4,362.75 (-0.90%)
DOW   34,298.76 (-0.41%)
QQQ   360.86 (-1.01%)
AAPL   175.31 (-0.10%)
MSFT   321.97 (+0.37%)
META   299.96 (+0.10%)
GOOGL   131.80 (-1.45%)
AMZN   130.86 (-3.27%)
TSLA   259.57 (-1.15%)
NVDA   415.18 (-1.71%)
NIO   8.54 (-3.17%)
BABA   84.48 (-1.47%)
AMD   97.36 (-2.97%)
T   15.36 (-1.22%)
F   12.25 (-0.89%)
MU   68.96 (-1.03%)
CGC   0.83 (-5.23%)
GE   113.85 (-0.87%)
DIS   83.38 (+0.99%)
AMC   7.87 (-3.55%)
PFE   33.11 (-1.52%)
PYPL   58.93 (-3.17%)
NFLX   388.06 (+0.46%)
NASDAQ:QNRX

Quoin Pharmaceuticals (QNRX) Stock Forecast, Price & News

$5.20
0.00 (0.00%)
(As of 01:02 PM ET)
Compare
Today's Range
$5.05
▼
$5.30
50-Day Range
$5.18
▼
$9.09
52-Week Range
$5.04
▼
$43.20
Volume
11,664 shs
Average Volume
81,650 shs
Market Capitalization
$5.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

QNRX stock logo

About Quoin Pharmaceuticals (NASDAQ:QNRX) Stock

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; a Master Service Agreement with Therapeutics Inc.; and a research agreement with Queensland University of Technology. The company was founded in 2018 and is based in Ashburn, Virginia.

QNRX Price History

QNRX Stock News Headlines

September 16, 2023 | americanbankingnews.com
Quoin Pharmaceuticals (NASDAQ:QNRX) Trading Down 1.9%
August 9, 2023 | finance.yahoo.com
Quoin Pharmaceuticals' Commitment to Delivering Treatment for Netherton Syndrome Patients and Creating Value for Shareholders
September 21, 2023 | Chaikin Analytics (Ad)
Wall Street Legend Warns "Mass Bank Run" is Coming
Man who predicted 2023 bank run warns it could soon get worse. Get out of cash and into a new vehicle 50 years in the making. Click here to learn more.
August 3, 2023 | msn.com
Quoin Pharmaceuticals Ltd - ADR (QNRX) Price Target Increased by 1423.07% to 134.64
July 27, 2023 | finance.yahoo.com
Quoin Pharmaceuticals Announces Second Quarter 2023 Financial Results and Corporate Update Conference Call to be held on Thursday August 3rd at 8:30 am ET
July 21, 2023 | benzinga.com
What's Going On With Quoin Pharmaceuticals (QNRX) Stock Today?
July 17, 2023 | msn.com
Why Is BYND Cannasoft Enterprise (BCAN) Stock Down 46% Today?
July 17, 2023 | msn.com
Why Is Quoin Pharmaceuticals (QNRX) Stock Down 90% Today?
September 21, 2023 | Chaikin Analytics (Ad)
Wall Street Legend Warns "Mass Bank Run" is Coming
Man who predicted 2023 bank run warns it could soon get worse. Get out of cash and into a new vehicle 50 years in the making. Click here to learn more.
May 24, 2023 | finance.yahoo.com
Quoin Pharmaceuticals Announces 50% Enrollment in Open Label Netherton Syndrome Clinical Trial
May 12, 2023 | finanznachrichten.de
Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results
May 8, 2023 | finance.yahoo.com
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2023 Financial Results
May 5, 2023 | msn.com
A Preview Of Quoin Pharmaceuticals's Earnings
May 2, 2023 | finance.yahoo.com
Quoin Pharmaceuticals Announces First Quarter 2023 Financial Results and Corporate Update Conference Call to Be Held on Tuesday, May 9, 2023 at 8:30 am ET
March 22, 2023 | finance.yahoo.com
QNRX: Patients Dosed in Both Concurrent Studies; Potentially Adding New Assets to Product Portfolio
March 21, 2023 | finance.yahoo.com
Quoin Pharmaceuticals Doses First Patient in Open Label Netherton Syndrome Clinical Trial
March 11, 2023 | finance.yahoo.com
Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) Q4 2022 Earnings Call Transcript
March 9, 2023 | finanznachrichten.de
Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Provides Corporate Update and Announces Fourth Quarter and Full Year 2022 Financial Results
March 8, 2023 | msn.com
Quoin Pharmaceuticals GAAP EPS of -$0.41 beats by $0.19
March 2, 2023 | finance.yahoo.com
Quoin Pharmaceuticals Announces 2022 Corporate Update Conference Call to be held on Thursday March 9th at 8:30am ET
March 1, 2023 | finance.yahoo.com
A Pivotal Year Ahead for Quoin Pharmaceuticals
February 24, 2023 | seekingalpha.com
Quoin Pharmaceuticals plunge 45% on pricing $7M stock offering
February 22, 2023 | msn.com
Why Quoin Pharmaceuticals Shares Are Trading Lower By Over 40%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
February 22, 2023 | benzinga.com
Why Quoin Pharmaceuticals Shares Are Getting Obliterated Wednesday
February 22, 2023 | finance.yahoo.com
Quoin Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
December 13, 2022 | finance.yahoo.com
Quoin Pharmaceuticals Announces Dosing of First Patient in Clinical Trial in Netherton Syndrome
December 5, 2022 | finance.yahoo.com
QNRX: Moving QRX003 Forward in Concurrent Studies
See More Headlines
Receive QNRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Quoin Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

QNRX Company Calendar

Last Earnings
8/02/2023
Today
9/21/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:QNRX
CUSIP
N/A
CIK
1671502
Web
quoinpharma.com
Phone
(703) 980-4182
Fax
972-9767-8750
Employees
4
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($22.4186)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-9,380,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-106.57%
Return on Assets
-58.99%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
3.55
Quick Ratio
3.55

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$18.35 per share
Price / Book
0.28

Miscellaneous

Outstanding Shares
980,000
Free Float
956,000
Market Cap
$5.10 million
Optionable
Not Optionable
Beta
1.82
5G Stocks: The Path Forward is Profitable Cover
5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Michael Myers Ph.D. (Age 61)
    Co-Founder, CEO & Chairman
    Comp: $607.11k
  • Ms. Denise Carter (Age 54)
    Co-Founder, COO & Director
    Comp: $585.22k
  • Mr. Gordon Bruce Dunn J.D. (Age 59)
    Chief Financial Officer
    Comp: $361.38k

Key Competitors

View All Competitors













QNRX Stock - Frequently Asked Questions

Should I buy or sell Quoin Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Quoin Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" QNRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in QNRX, but not buy additional shares or sell existing shares.
View QNRX analyst ratings or view top-rated stocks.

How have QNRX shares performed in 2023?

Quoin Pharmaceuticals' stock was trading at $17.04 at the start of the year. Since then, QNRX stock has decreased by 69.5% and is now trading at $5.20.
View the best growth stocks for 2023 here.

Are investors shorting Quoin Pharmaceuticals?

Quoin Pharmaceuticals saw a decrease in short interest in August. As of August 31st, there was short interest totaling 9,300 shares, a decrease of 30.6% from the August 15th total of 13,400 shares. Based on an average daily volume of 158,600 shares, the short-interest ratio is presently 0.1 days.
View Quoin Pharmaceuticals' Short Interest.

When is Quoin Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our QNRX earnings forecast.

How were Quoin Pharmaceuticals' earnings last quarter?

Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) announced its quarterly earnings data on Wednesday, August, 2nd. The company reported ($2.13) earnings per share for the quarter.

When did Quoin Pharmaceuticals' stock split?

Quoin Pharmaceuticals shares reverse split before market open on Monday, July 17th 2023. The 1-12 reverse split was announced on Monday, July 17th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, July 17th 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

What is Quoin Pharmaceuticals' stock symbol?

Quoin Pharmaceuticals trades on the NASDAQ under the ticker symbol "QNRX."

How do I buy shares of Quoin Pharmaceuticals?

Shares of QNRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Quoin Pharmaceuticals' stock price today?

One share of QNRX stock can currently be purchased for approximately $5.20.

How much money does Quoin Pharmaceuticals make?

Quoin Pharmaceuticals (NASDAQ:QNRX) has a market capitalization of $5.10 million. The company earns $-9,380,000.00 in net income (profit) each year or ($22.4186) on an earnings per share basis.

How can I contact Quoin Pharmaceuticals?

Quoin Pharmaceuticals' mailing address is 23 HATA`AS STREET, KFAR SABA L3, 44425. The official website for the company is quoinpharma.com. The company can be reached via phone at (703) 980-4182, via email at ir@cellectbio.com, or via fax at 972-9767-8750.

This page (NASDAQ:QNRX) was last updated on 9/21/2023 by MarketBeat.com Staff

My Account -